ArticlePloS one2022

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells.

Edris Choupani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.